- Home
- NNOX vs CDTX Comparison
NNOX vs CDTX Comparison
Compare NNOX & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NNOX | CDTX |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical Electronics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.8M | 2.8B |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | NNOX | CDTX |
|---|---|---|
| Price | $3.23 | $220.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $8.50 | ★ $128.75 |
| AVG Volume (30 Days) | ★ 2.7M | 2.3M |
| Earning Date | 11-20-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,302,000.00 | N/A |
| Revenue This Year | $20.19 | N/A |
| Revenue Next Year | $137.69 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 15.19 | N/A |
| 52 Week Low | $2.78 | $15.22 |
| 52 Week High | $11.00 | $221.20 |
Technical Indicators
Market Signals| Indicator | NNOX | CDTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.09 | 86.62 |
| Support Level | $3.62 | $219.60 |
| Resistance Level | $3.88 | $220.38 |
| Average True Range (ATR) | 0.25 | 0.74 |
| MACD | -0.08 | -3.92 |
| Stochastic Oscillator | 1.66 | 67.82 |
Price Performance
Historical ComparisonAbout NNOX NANO-X IMAGING LTD
Nano X Imaging Ltd is engaged in the business of manufacturing medical imaging systems. It offers a Nanox System which is a combination of hardware and software. It develops a prototype of the Nanox.ARC, a medical imaging system incorporating its novel digital X-ray source; and Nanox.CLOUD, a companion cloud-based software that will allow for the delivery of medical screening as a service. It has three business segments: Nanox.ARC division, the radiology services division and the AI solutions division. Key revenue is generated from Radiology Services.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.